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The Effects of Galantamine Hydrobromide Treatment   
on Dehydroepiandrosterone Sulfate and Cortisol Levels 
in Patients with Chronic Fatigue Syndrome 
 
 
 
ObjectiveaaMental fatigue, cognitive disorders, and sleep disturbances seen in chronic fa-
tigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of 
cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypo-
activity seen in CFS. Therefore, we investigated the alterations in stress hormones such as 
cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4-
week administration of galantamine hydrobromide, a selective acetylcholinesterase inhibitor, 
and aimed to investigate whether there are any relationships between the probable hormo-
nal changes and cholinergic treatment. 
MethodsaaBasal levels of cortisol and DHEAS were measured in 29 untreated CFS pa-
tients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 
20 healthy controls. In the patient group, four weeks after 8 mg/d galantamine hydrobro-
mide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 pa-
tients who stayed in study were divided into two subgroups as responders and nonresponders 
according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) 
scores. 
ResultsaaImportant findings of this study are lower pre-and post-treatment cortisol levels 
and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, res-
pectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which 
were normalized following four weeks’ treatment with 8 mg/d galantamine hydrobromide 
in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively). 
ConclusionaaThe findings of the decrease in basal DHEAS levels and DHEAS/cortisol 
molar ratios normalizing with galantamine treatment may give some support to the cho-
linergic deficit hypothesis in CFS. 
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Introduction 
 
Diagnostic criteria for chronic fatigue syndrome (CFS) include lymphadenopathy, 
sore throat, cognitive impairment, headache, muscle and joint pains and tiredness fol-
lowing activity in addition to fatigue that lasts for more than six months, leading to
disability and that does not improve with rest.
1 Psychiatric co-morbid conditions like 
depression and anxiety are present in almost 50% of patients.
2 These co-morbid con-
ditions complicate the evaluation of endocrine disorders like dysfunction in the hy-
pothalamic-pituitary-adrenal (HPA) axis. 
The etiology of CFS is not clear. However, accumulating data suggest that underly-
ing pathophysiology of stress related disorders such as CFS involves alterations in the 
reactivity of HPA axis response to physical and psychosocial stress and as a consequ- 
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ence it might cause a HPA axis switch from hyper-to 
hypofunction position.
3 Hypocortisolism, which appears 
as a cardinal feature of CFS without psychiatric comor-
bidity, does not seem to be explained by only inactivity.
4,5 
The presence of hypocortisolism in CFS has been shown 
by low cortisol levels in 24-hour urine,
6-8 by low serum 
cortisol levels early in the morning,
9,10 and by low saliva 
cortisol levels.
11 
Recently, dehydroepiandrosterone (DHEA) produced 
in the zona reticularis of the adrenal cortex and its more 
stable sulfate derivative (dehydroepiandrosterone sulfate, 
DHEAS) became the focus of attention in addition to 
glucocorticoids produced in the zona fasciculate in CFS. 
DHEA and DHEAS are neurosteroids that are also pro-
duced in the brain and their release from adrenal cortex 
is under the control of adrenocorticotrophic hormone 
(ACTH).
12 They have a diurnal rhythm similar to cor-
tisol, that is to say their maximum release is early in the 
morning just before awakening.
13,14 Plasma levels of 
DHEAS are more stable than DHEA and may be a bet-
ter measure of adrenal androgen turnover.
15 
Parker et al.
16 proposed that there was a symbiosis be-
tween DHEA and cortisol production and that this pro-
duction shifted from androgens to glucocorticoids for 
homeostasis during psychological or physical stresses. 
However, in CFS, which is a stress-related disorder, the 
metabolic shift expected from DHEA to cortisol was not 
observed during physiological stress.
17 Another study 
showed impaired DHEA responsiveness to stimulation 
with synthetic ACTH in CFS patients.
18  
Studies conducted in both animals and humans demon-
strate positive effects of DHEA and DHEAS on memory 
(promnestic effects) by increasing acetylcholine release 
from the hippocampus.
19,20 Its levels are found to be low 
in conditions associated with memory impairment.
21 Men-
tal fatigue and cognitive disorders in CFS may be attri-
buted to cholinergic deficit. Acetylcholine has a general 
steroidogenic effect and this effect is mediated by ACTH 
via muscarinic receptors.
22-24 Under conditions of stress, 
acetylcholine facilitates the release of corticotropin-re-
leasing hormone (CRH). A functional deficiency of cho-
linergic neurotransmission may cause the HPA axis hy-
poactivity seen in CFS since cholinergic activity poten-
tially stimulates the HPA axis.
25 Sleep disturbances are 
common in patients with CFS and may be due to a cen-
tral cholinergic deficiency.
26 Galantamine hydrobromide 
is a selective acetylcholinesterase inhibitor. In a rando-
mized controlled study it was found that galantamine did 
not have any therapeutic effect in CFS patients.
26 In ano-
ther uncontrolled study, it was administered to CFS pa-
tients with slight psychiatric features for two weeks at a 
dose of 10 mg/d, and it was reported that fatigue, sleep 
disorder, and myalgia symptoms improved significantly.
27 
There have been few studies evaluating the effect of ga-
lantamine on cortisol levels. The findings of these studies 
are inconsistent. Although a study showed increased cor-
tisol levels by galantamine,
28 in a recent study no galanta-
mine treatment effect on cortisol levels was demonstrated.
26 
In this study, we investigated probable alterations in 
stress hormones such as cortisol and DHEAS in CFS pa-
tients before and after the treatment with galantamine hy-
drobromide. 
 
Methods 
 
Subjects 
Twenty-nine CFS patients who were diagnosed accord-
ing to Centers for Disease Control (CDC)1 criteria (20 fe-
males and 9 males; mean age: 41.89±8.53 years; mean 
disease duration: 80.13±57.16 months) and 20 healthy 
controls (16 females and 4 males; mean age: 42.50±9.42 
years) were included in the study. The patients were se-
lected consecutively from the outpatient population of 
the Psychiatry Clinic of Erciyes University Medical School. 
None of the patients was or had ever been diagnosed with 
any psychiatric disease according to Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th Edition, Text 
Revision (DSM-IV TR) criteria.
29 The control group in-
cluded healthy hospital personnel who did not have any 
psychiatric disease history or diagnosis. Medical disor-
ders (e.g. neurological, endocrinological, or metabolic) 
were excluded through the history, clinical examinations, 
and the evaluation of the results of the laboratory tests 
in all subjects. None of the subjects was using any me-
dication or oral contraceptive drug that could affect the 
functions of the HPA axis. The female subjects were all 
pre-menopausal.  
This study was approved by the local Ethics Committee. 
Written informed consent was obtained from each subject 
after the study was explained to them. 
 
Procedure 
In the patients the first stage involved a standard cli-
nical evaluation and the administration of the following 
clinical scales: the Hamilton Depression Rating Scale 
(HAM-D);30 Hamilton Anxiety Rating Scale (HAM-A);31 
and Newcastle Research Group ME/CFS Score Card 
(NRG),
32 which consists of 10 items and measures the 
physical and cognitive functions, and on which a score 
of ≥15 is highly suggestive of CFS. After this, catheters 
were placed in the forearm veins of the subjects at 8.00 
am after a starvation period of 12 hours and, following a 
resting period of 30 minutes, blood samples were col-
lected into tubes. The samples were centrifuged directly.  
 
 
 
 
Galantamine Hydrobromide Treatment and Chronic Fatigue Syndrome 
206 Psychiatry Invest 2009;6:204-210 
Separated serum samples were stored at -70℃. Basal 
blood samples of the female patients were obtained be-
tween the 4th and 7th days of their menstrual cycles. Then, 
all patients were started on fixed dose 8 mg/d oral gal-
antamine hydrobromide. After four weeks of treatment, 
the same psychiatric measures and blood sampling pro-
cedure were repeated in the patients. However, seven 
patients were later excluded as they were unable to to-
lerate the treatment because of nausea or would not agree 
to cooperate, and the study continued with 22 patients. 
The same psychiatric measures and blood taking proce-
dure for hormonal values were carried out only once in 
healthy controls. 
At the end of the treatment period we separated our 
patients into two subgroups: responders (n=10) and non-
responders (n=12). Twenty percent and more reductions 
in NRG scores were accepted as a response to treatment 
arbitrarily.
32 
 
Hormone analyses 
Serum cortisol levels [{Diagnostic System Laborato-
ries (DSL, Webster, TX, USA) DSL-2100 reagents}, (sen-
sitivity: 0.3 μg/dL, coefficient of variation: 8.4)] and 
DHEAS levels [{DSL (Webster, TX, USA) DSL-3500 
reagents}, (sensitivity: 17.0 ng/mL, coefficient of variat-
ion: 6.3)] were measured by the radioimmunoassay (RIA) 
method. 
 
Statistical analyses 
Data distributions for each hormonal evaluation were 
normal according to the Kolmogorov-Smirnov test. The 
patients and controls were compared with respect to sex 
using the χ2 test. The significance of differences between 
age, body mass index (BMI), and clinical scale scores of 
the patients and controls was assessed with a t-test for 
independent groups. To compare hormone levels of the 
patients and controls a two-way analysis of variance (AN-
OVA) test was performed by taking the presence of dis-
order and gender as fixed factors, and age and BMI as 
covariates. A repeated measure ANOVA test was carried 
out for the comparison of the hormone levels of the pa-
tients before and after the treatment. The same tests were 
used for analyses of subgroups according to the response 
to the treatment (responders and non-responders). Pear-
son’s correlation test was performed to investigate the 
relationships between hormone levels and clinical and de-
mographical variables in the patients and controls. The 
changes in hormonal values and those in clinical scales 
were calculated as delta values by subtracting the post-
treatment values from the pre-treatment values. 
 
Results 
 
No statistically significant differences were observed 
between the two groups according to age, gender, or BMI 
variants. The scores of clinical scales in the patients with 
CFS were higher than those in the controls (Table 1). NRG 
scores were decreased after the treatment compared to 
the pre-treatment values of the patients (Table 2).  
The pre-treatment basal cortisol levels of the patients 
were significantly lower than those of the controls (F= 
4.129, p=0.049). No significant difference was found in 
TABLE 2. Comparison of clinical scale scores of the patients before and after the treatment
Patient group 
Clinical scale scores  Before treatment (N=29) 
Mean±SD 
After treatment (N=22) 
Mean±SD 
Comparisons 
HAM-D score  08.40±3.96  07.50±3.62  t=0.843  p=0.409 
HAM-A score  12.27±5.81 10.72±4.68  t=1.242  p=0.228 
NRG score  17.95±1.39 16.09±3.25*  t=2.697  p=0.013 
*Significantly lower than those in pre-treatment values. HAM-D: Hamilton Depression Rating Scale, HAM-A: Hamilton Anxiety Rating Scale, 
NRG: Newcastle Research Group ME/CFS Score Card   
TABLE 1. Socio-demographic and clinic characteristics of the patient and control groups
Demographic and clinical 
variable 
Patient group (N=29) 
Mean±SD 
Control group (N=20) 
Mean±SD 
Comparisons 
Gender (Male/Female) 9/20  4/16  χ2=0.7390  p=0.390 
Age 41.89±8.53 42.50±9.42 t=0.2330  p=0.817 
BMI 27.26±3.66 27.15±5.54 t=0.0850  p=0.933 
Disease duration (months) 80.13±57.16 -  - 
HAM-D score  08.00±3.72*  01.45±1.90 t=8.0670  p<0.001 
HAM-A score  11.89±5.38*  03.50±2.91 t=6.3530  p<0.001 
NRG score  17.89±1.47*  01.40±1.78 t=35.301    p<0.001 
*Significantly higher than those of the controls. n: number of subjects, BMI: Body Mass Index, HAM-D: Hamilton Depression Rating Scale, 
HAM-A: Hamilton Anxiety Rating Scale, NRG: Newcastle Research Group ME/CFS Score Card 
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serum DHEAS levels between the patients and the controls 
before the treatment (F=2.811, p=0.101), although the pa-
tients had elevated DHEAS/cortisol molar ratios compared 
to the controls (F=7.318, p=0.010). The cortisol values of 
the patients continued to be low after the treatment com-
pared to the controls (F=4.803, p=0.035); however, the 
post-treatment basal DHEAS values and DHEAS/corti-
sol molar ratios were similar to those of the controls (F= 
0.153, p=0.698; F=3.026, p=0.090; respectively)(Table 3). 
In the patient group, there was no significant differ-
ence in serum cortisol levels and DHEAS/cortisol molar 
ratio of the patients between before (mean±SD: 11.19± 
4.83 for cortisol, 136.32±90.34 DHEAS/cortisol molar 
ratio) and after (mean±SD: 10.71±3.93 for cortisol, 114.18 
±75.99 for DHEAS/cortisol molar ratio) the treatment, 
according to a repeated measure ANOVA test (F=1.012, 
p=0.328; F=0.546, p=0.470; respectively). After the treat-
ment DHEAS levels (mean±SD: 1114.77±638.60) were 
significantly decreased compared to those before the treat-
ment (mean±SD: 1536.37±1094.72)(F=6.723, p=0.018). 
When the CFS patients were separated as responders 
and nonresponders to the treatment, serum cortisol values 
of the two subgroups did not differ from those of the con-
trols before or after the treatment. The pre-treatment DH-
EAS values and DHEAS/cortisol molar ratios of the res-
ponders were significantly higher than those of the con-
trols (F=5.382, p=0.029; F=5.722, p=0.025 respectively). 
No significant difference was found in the pre-treatment 
DHEAS/cortisol molar ratios between the non-respon-
ders and the controls (F=3.627, p=0.067). There were no 
statistically significant differences in the pre-treatment 
DHEAS values and DHEAS/cortisol molar ratios be-
tween the responders and the non-responders (F=2.902, 
p=0.107; F=1.082, p=0.313 respectively). A comparison 
of the pre-treatment and the post-treatment hormone values 
demonstrated that the pre-treatment DHEAS values were 
only significantly higher than the post-treatment DHEAS 
values in responders (F=12.119, p=0.013)(Table 4)(Fig-
ure 1). 
No statistically significant difference was found in the 
hormonal changes between the male patients and the fe-
male patients (Z=0.274, p=0.820 for delta cortisol, Z= 
1.528, p=0.140 for delta DHEAS, Z=1.293, p=0.218 for 
delta DHEAS/cortisol ratio). 
A negative correlation was observed between the DH-
EAS values and age in the patient and control groups as 
TABLE 3. Hormonal values before and after treatment in the patient and control groups
Patient group 
Hormonal variables  Before treatment (N=29) 
Mean±SD 
After treatment (N=22) 
Mean±SD 
Control group (N=20) 
Mean±SD 
Basal cortisol (μg/dL)  0011.36±4.53*  0010.71±3.93*  0016.15±11.89 
Basal DHEAS (ng/mL) 1536.37±1094.72 1114.77±638.60† 1051.05±665.25 
DHEAS/Cortisol molar ratio  0143.84±86.14‡  0114.18±75.99  0083.31±55.08 
*Significantly lower than that of the control group (F=4.129, p=0.049; F=4.80 3, p=0.035), †Significantly lower than before the treatment 
(F=6.723, p=0.018), ‡Significantly higher than that of the control group (F=7.318, p=0.010). DHEAS: Dehydroepiandrosterone sulfate 
 
TABLE 4. Hormonal values of responders and non-responders before and after treatment
Responders Non-responders 
Hormonal variables  Before treatment 
(N=10) 
Mean±SD 
After treatment 
(N=10) 
Mean±SD 
Before treatment 
(N=12) 
Mean±SD 
After treatment 
(N=12) 
Mean±SD 
Control group 
(N=20) 
Mean±SD 
NRG score  0018.20±0.92  0013.90±3.34*  0017.75±1.71  0017.91±1.73  0001.40±1.78 
Cortisol (μg/dL)  0012.23±4.75  0010.45±2.68  0010.32±4.93  0010.92±4.85  0016.15±11.89 
DHEAS (ng/mL) 1744.30±1493.66† 1164.30±756.32 1122.41±529.80 1073.50±553.58 1051.05±665.25 
DHEAS/Cortisol  0145.75±111.76‡  0121.00±95.86  0128.47±72.21  0108.49±58.55  0083.31±55.08 
*Lower than pre-treatment (t=4.502, p=0.001), †Higher than post-treatment and controls (F=12.119, p=0.013; F =5.382, p=0.029), ‡Higher 
than controls (F=5.722, p=0.025). NRG: Newcastle Research Group ME/CFS Score Card, DHEAS: dehydroepiandrosterone sulfate 
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FIGURE 1. Basal serum DHEAS values of responders and non-
responders before and after treatment and the controls. DHEAS:
dehydroepiandrosterone sulfate.  
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expected (r=-0.601, p=0.001; r=-0.513, p=0.021; respec-
tively). There were strong positive correlations between 
the changes in the DHEAS values (delta DHEAS) and 
those in scores of depression (delta HAM-D) and anxiety 
scores (delta HAM-A) in the responder group (r=0.831, 
p=0.003; r=0.790, p=0.007; respectively), but not in the 
non-responder group (r=0.393, p=0.207; r=0.525, p=0.080; 
respectively). The correlation between delta DHEAS 
and delta NRG scores was not statistically significant in 
the responder or non-responder groups (r=0.589, p=0.073; 
r=0.350, p=0.265; respectively). No correlation was found 
between the changes in DHEAS/cortisol and those in 
clinical scales. 
 
Discussion 
 
The important findings of this study are: 1) the ab-
sence of any effect of the galantamine treatment on low-
ered cortisol levels in CFS patients, 2) higher basal DH-
EAS values and higher DHEAS/cortisol molar ratios 
which were normalized following four weeks’ treatment 
with 8 mg/d galantamine hydrobromide in the treatment-
respondent group. 
 
Hypocortisolism  
Many studies of patients with CFS have found HPA 
axis dysregulation and hypocortisolism. In these studies 
cortisol levels were decreased in 24-hour urine,
7 serial 
blood samples,
10 or saliva,
11 as seen in our study, but it 
is not clear whether low cortisol levels and HPA hypo-
function in CFS are a cause or result of the illness. Tak-
ing into account the finding of this study of the reduced 
cortisol levels of the pre-and post-treatments, we can 
infer that HPA alterations in CFS are the persisting fea-
tures of the disease, although we do not make any sug-
gestions as to whether it is a cause or a consequence of 
the illness. Reduced HPA axis functioning
6 has also 
been suggested to cause some of the symptoms, like re-
duced energy, post-exertional malaise, and headaches
1 
seen in CFS patients. In a previous study 5-10 mg/d hy-
drocortisone therapy resulted in a fall in fatigue scores 
of 34%.
33 One explanation for hypocortisolism in CFS 
may be increased glucocorticosteroid receptor sensitivity.
34 
The finding of unchanged cortisol level after galanta-
mine treatment of this study is consistent with a recent 
study by Blacker et al.
26 
How can we explain the finding of the study that while 
cortisol levels remained lower throughout the galantamine 
treatment some patients showed symptomatic improve-
ment at partial level? It has been suggested that a func-
tional deficiency of cholinergic neurotransmission may 
result in hypoactive HPA axis under stress conditions
35 
and may have a role at pathophysiology of CFS. Cho-
linergic neurotransmission stimulates growth hormone 
and insulin-like growth factor I secretions, which plays 
an important role in the regenerative functions of the pe-
ripheral nerves and skeletal muscles.
35 Taking together 
these findings, increased cholinergic activity by galanta-
mine treatment might trigger well-being independently 
of cortisol levels in some patients. This means, at least in 
some patients, that it may not be necessary to normalize 
cortisol levels for an improvement to be achieved. How-
ever, if we followed the patients in the long-term we 
could have a better idea about cortisol levels. As a con-
clusion we can suggest that in some patients with CFS 
there may be dysregulation in other systems like the 
cholinergic system along with the HPA axis.   
 
Dehydroepiandrosterone sulfate levels and  
dehydroepiandrosterone sulfate/cortisol molar 
ratios 
Given the findings of lower pre- and post-treatment 
cortisol levels, higher pre-treatment DHEAS levels com-
pared to post-treatment, and higher DHEAS/cortisol mo-
lar ratios in the patient group, we can suggest that there 
may be a disturbance in the ‘metabolic shift’ from an-
drogens to glucocorticoids.   
DHEA/cortisol or DHEAS/cortisol molar ratios were 
used in many studies as variants that reflected the home-
ostasis between androgens and glucocorticoids at adrenal 
level.
17,36 Scott et al.
37 performed a study in CFS patients 
without any psychiatric comorbidity. They found that 
DHEA and DHEAS levels were lower than in healthy 
controls and explained this finding with mild adrenal 
cortical atrophy (failure) secondary to ACTH deficiency. 
Scott et al.
37 also did not identify any difference between 
CFS patients, depressives, and healthy controls with res-
pect to basal cortisol levels. De Becker et al.
38 demons-
trated that basal DHEA levels were normal, but DHEA 
responses to ACTH stimulation were blunted in CFS 
patients. No cortisol levels were reported in that study. 
Cleare et al.
36 found higher basal DHEA levels in CFS 
patients with no psychiatric comorbidity compared to 
healthy controls; however, they did not report any differ-
ence in DHEAS levels. In the same study, they did not 
find any difference between patients and controls with 
respect to cortisol/DHEA molar ratio. In addition, the 
investigators administered low dose (5-10 mg/d) hydro-
cortisone to CFS patients and determined significant de-
creases in DHEA levels in patients who reported declin-
ed fatigue scores with treatment. They found significant 
reductions in DHEAS after hydrocortisone treatment. 
Similarly, we also found decreased DHEAS levels after 
galantamine treatment in CFS patients. This may be in- 
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terpreted as the fact that the acetylcholinergic effect of 
galantamine facilitates the release of CRH hormone and 
in turn, causes elevated DHEAS levels to decrease th-
rough recovering the existing tentative disturbance in 
metabolic shift from cortisol to DHEAS. 
Some studies have reported low
39,40 or normal
36,41 mor-
ning DHEAS levels in CFS patients. An investigator re-
ported a slightly high DHEA levels in CFS patients.
18 Si-
milarly, Goldberg and Lichten
42 reported DHEAS levels 
above the reference limit in 20% of their patient group, 
made up of 140 females with CFS. In our study increa-
sed pre-treatment DHEAS/cortisol molar ratio may have 
been due to impaired HPA axis activity and decreased 
cortisol levels or a defect in metabolic shift from andro-
gen to glucocorticoid production. It was proposed that 
the literature findings about higher cortisol/DHEA molar 
ratios in major depression were the most important indica-
tors of excessive cortisol exposure of the brain.
43,44 On the 
other hand, our finding of high DHEAS/cortisol molar 
ratios might lead to further decreases in the low cortisol 
effects on the brain. However, only basal levels were in-
vestigated in this study. Circadian measurements might 
provide further information on this subject. 
The controversies in all these studies might be explained 
by the differences in clinical characteristics (psychiatric 
comorbidity, medicines), methodological discrepancies 
(differences in the timing of blood sampling or laboratory 
techniques), and other factors that might affect functions of 
the HPA axis, like inactivity. Our study had the advantages 
of including pure and untreated CFS patients.   
 
Responders and non-responders to treatment 
When we separated our patients into two subgroups 
as responders and non-responders to treatment, the pre-
treatment basal DHEAS levels and DHEAS/cortisol mo-
lar ratios of the responders were significantly higher than 
those of the controls; however, it was interesting to find 
the values of the non-responders similar to those of the 
controls. To our knowledge, these findings are unique in 
the literature. It was concluded that high levels of pre-
treatment DHEAS activity and its ratio to cortisol might 
be an indicator of the responsiveness to treatment. 
It is possible to explain the high pre-treatment basal 
DHEAS levels and DHEAS/cortisol molar ratio in res-
ponders and the decrease in DHEAS levels with galan-
tamine hydrobromide treatment in all CFS patients and 
especially in responders in several ways. The first is that 
high pre-treatment DHEAS levels and DHEAS/cortisol 
molar ratio in responders may be due to hypocortisolism 
supposed to be present in CFS. Improvement in relative 
hypocortisolism with treatment may provide a return to 
the normal DHEAS pattern. However, we did not ob-
serve any significant increase in cortisol levels. A longer 
period might be needed for such a finding. The second 
possible explanation is that some abnormalities in the me-
tabolic pathway of DHEAS like 21-hydroxylase enzyme 
deficit
42 may lead to higher pre-treatment DHEAS syn-
thesis. The third is that normalization of high DHEAS 
levels in responders may be secondary to improvement 
in some clinical features such as sleep disturbances, an-
xiety or some depression symptoms which may be avail-
able in these patients.
45 Indeed, the finding of the present 
study of a positive correlation between reduction of the 
DHEAS levels with galantamine treatment and recovery 
in clinical depression and anxiety scales in only respon-
dent patients supports this hypothesis strongly. The fourth 
is that abnormal glucocorticoid receptor sensitivity may 
improve with treatment and the production may shift 
from DHEAS to cortisol. Finally, the cholinergic effect 
of galantamine that facilitates release of CRH may cause 
reduction in DHEAS levels and the normalization of 
high DHEAS/cortisol molar ratio. We think that the du-
ration of our experimental treatment may not have been 
sufficient to show these changes. 
There are several limitations of the study. A small num-
ber of patients and the absence of placebo control group 
might have prevented us from observing the therapeutic 
and hormonal effects of the galantamine more accura-
tely. Additionally, the short duration of the treatment 
might obscure the long-term effects of the drug on fati-
gue scores or on the hormones such as cortisol. 
In conclusion, decreases in basal DHEAS levels and 
DHEAS/cortisol molar ratios in CFS patients with gal-
antamine treatment may somewhat support the hypothe-
sis that cholinergic deficit may be present in CFS. On 
the other hand, DHEAS findings of responders suggest 
that high pre-treatment values of this hormone may be 
an indicator of the treatment responsiveness. If DHEA 
and DHEAS levels play an important role in CFS phy-
siopathology, we think that, in addition to the employ-
ment of non-invasive techniques like the measurement 
of cortisol levels in the saliva, the evaluation of DHEA 
(-S) levels with response to naturalistic stressors (chal-
lengers) like exercise or social stress in future studies 
will be beneficial. 
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